Genscript Biotech Corporation (GENSCRIPT BIO) approved the issuance of 14.74 million restricted share units (RSUs) on 4 June 2026 under its 2021 RSU Scheme. The award will be settled entirely with new shares to be issued within the existing scheme mandate limit.

Key grant metrics • Total RSUs: 14.74 million, representing 0.6734% of the current issued share capital and 0.6689% on a fully-diluted basis after issuance. • Market reference: Closing price on the grant date was HK$12.99; no purchase price is payable by grantees.

Allocation • Executive Directors: 508,684 RSUs distributed among Chairman Robin Meng (169,561), and executive directors Frank Zhang, Li Zhu and Sally Wang (113,041 each). • Rotating CEO Weihui (Sherry) Shao: 841,470 RSUs. • Employees: 13.36 million RSUs to selected staff across the Group. • Service provider (consultant): 30,153 RSUs.

Vesting framework • Directors: Three-year vesting in annual tranches from 31 Aug 2027 to 31 Aug 2029. • CEO: Five-year vesting in annual tranches from 31 Aug 2027 to 31 Aug 2031. • Employees: One- to three-year schedules ending no later than 31 Aug 2029; one senior employee has a mixed schedule beginning 31 Aug 2026 with clawback if employment ceases within the first year. • Service provider: Three-year vesting in annual tranches through 31 Aug 2029.

Performance and clawback conditions RSUs granted to directors, the CEO and employees are subject to individual performance targets, adherence to corporate culture standards, and a clawback mechanism covering misconduct or financial restatement. No performance targets or clawback provisions apply to the service provider’s award.

Remaining capacity Following the grant and after accounting for 223,305 lapsed awards, 188.23 million shares remain available under the overall scheme mandate limit, with 21.04 million shares still available under the service-provider sub-limit.